- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Spectral CT System Gets FDA Clearance for Radiation Oncology Use
The Spectral CT 7500 RT system reportedly combines 4D conventional computed tomography (CT) with the enhanced quantification and visualization of spectral CT to facilitate improved precision with radiotherapy.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Spectral CT 7500 RT system, which enables clinicians to access the capabilities of 4D conventional computed tomography (CT) and spectral CT in one scan.
Geared to radiation oncology, the Spectral CT 7500 RT system bolsters tissue characterization with spectral CT, facilitating targeted radiotherapy, according to Philips, the manufacturer of the Spectral CT 7500 RT system.
The newly FDA-cleared Spectral CT 7500 RT system bolsters tissue characterization with spectral CT, and offers automated stopping-power ratio (SPR) mapping and direct electron density to improve the accuracy of radiotherapy dosing. (Image courtesy of Philips.)
Emphasizing that the Spectral CT 7500 RT system is the first radiation therapy CT platform to provide respiratory-gated spectral imaging, Philips said the system offers automated stopping-power ratio (SPR) mapping and direct electron density to improve the accuracy of radiotherapy dosing.
"The Spectral CT system provides us with several capabilities that conventional CT does not have. It can provide electron density and effective atomic number results, which we can convert to the proton stopping-power ratio. And published data shows that the stopping power ratio obtained in this way has fewer uncertainties compared to regular calibration curves, thereby reducing the uncertainty margins during treatment planning," noted Zhong Su, Ph.D., the physics director in the Department of Radiation Oncology at the University of Arkansas for Medical Sciences (UAMS) Medical Center in Little Rock, Arkansas.
Philips noted the Spectral CT 7500 RT system will be showcased at the upcoming Radiological Society of North America (RSNA) Annual Meeting in Chicago December 1-5, 2024.
What Emerging CT Research Reveals About Obesity and Post-Op Survival for Non-Small Cell Lung Cancer
January 29th 2025For those without low skeletal muscle mass on CT and myosteatosis, obese patients have a 23 percent lower risk of death than non-obese patients after undergoing curative resection for non-small cell lung cancer, according to newly published research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
